Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1240 studies found for:    Open Studies | "Lymphoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
2 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: CD19-targeted CAR-T cells
3 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
4 Recruiting Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
5 Recruiting Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Condition: B-cell Lymphoma
Interventions: Drug: SD-101;   Radiation: Radiation therapy
6 Not yet recruiting A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Biological: SAIT101;   Biological: MabThera®
7 Not yet recruiting Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Condition: Lymphoma
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: Methotrexate
8 Recruiting CD19-targeting CAR T Cells for B Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Biological: CD19-targeting CAR T Cells infusion
9 Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
10 Recruiting CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Condition: Lymphomas
Intervention: Genetic: Anti-CD30 CAR T cells
11 Recruiting Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
Condition: Lymphoma
Intervention: Radiation: Radiation Therapy
12 Recruiting Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Pembrolizumab
13 Recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
14 Not yet recruiting A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Blinatumomab
15 Recruiting Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
Condition: Lymphoma
Interventions: Drug: Rituximab;   Radiation: Radiation
16 Recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
17 Recruiting Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: thiotepa;   Procedure: stem cell transplant;   Drug: G-CSF
18 Recruiting Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)
Condition: Lymphoma
Intervention:
19 Recruiting Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Intervention: Other: Any treatment, watch and wait policy included
20 Recruiting A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Condition: B-Cell Lymphoma
Intervention: Drug: CPI-1205

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.